A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Qianqian, Zhang, Fuwu, Liu, Yijing, Wang, Zhantong, Yu, Guocan, Liang, Brian, Niu, Gang, Su, Ting, Zhu, Guizhi, Lu, Guangming, Zhang, Longjiang, Chen, Xiaoyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080439/
https://www.ncbi.nlm.nih.gov/pubmed/32206706
http://dx.doi.org/10.1126/sciadv.aaw6071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080439/
https://www.ncbi.nlm.nih.gov/pubmed/32206706
http://dx.doi.org/10.1126/sciadv.aaw6071

Ejemplares similares